Harumi Yoshinaga
Overview
Explore the profile of Harumi Yoshinaga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
627
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pina-Garza J, Villanueva V, Rosenfeld W, Yoshinaga H, Patten A, Malhotra M
Epilepsy Behav
. 2022 Sep;
135:108901.
PMID: 36122531
Objective: This post hoc analysis of four open-label extension (OLEx) studies evaluated the long-term efficacy and safety of adjunctive perampanel in adolescent patients (aged 12 to ≤17 years) with focal-onset...
2.
Yoshinaga H, Benitez A, Takeda S, Fournier M, Kugler A
Epilepsy Res
. 2021 May;
174:106651.
PMID: 34020149
Background: In Japan, intravenous (IV) administration of antiepileptic drugs in a healthcare setting is the preferred treatment option that is both licensed and recommended for initial treatment of status epilepticus...
3.
Hanaoka Y, Akiyama T, Yoshinaga H, Miyamoto R, Kawarai T, Kaji R, et al.
Brain Dev
. 2021 Apr;
43(7):783-788.
PMID: 33832800
Background: DYT-TOR1A is caused by a GAG deletion in the TOR1A gene. While it usually manifests as early-onset dystonia, its phenotype is extremely diverse, even within one family. Recent reports...
4.
Pina-Garza J, Rosenfeld W, Saeki K, Villanueva V, Yoshinaga H, Patten A, et al.
Epilepsy Behav
. 2020 Jan;
104(Pt A):106876.
PMID: 31954998
Objective: This post hoc analysis of six randomized, double-blind, Phase II and III studies evaluated efficacy and safety of adjunctive perampanel (2-12 mg/day) in adolescent patients (aged ≥12 to ≤17 ...
5.
Tanaka M, Natsume J, Hamano S, Iyoda K, Kanemura H, Kubota M, et al.
Brain Dev
. 2019 Oct;
42(1):28-34.
PMID: 31604594
Objective: To investigate the effect of guidelines for management of febrile seizures on the clinical practice, we conducted a nationwide survey in Japan. Methods: The Japanese guidelines for management of...
6.
Itoh M, Dai H, Horike S, Gonzalez J, Kitami Y, Meguro-Horike M, et al.
Brain
. 2019 Feb;
142(3):560-573.
PMID: 30715177
The leukodystrophies cause severe neurodevelopmental defects from birth and follow an incurable and progressive course that often leads to premature death. It has recently been reported that abnormalities in aminoacyl...
7.
Tsuchiya H, Akiyama T, Kuhara T, Nakajima Y, Ohse M, Kurahashi H, et al.
Brain Dev
. 2018 Nov;
41(3):280-284.
PMID: 30384990
Dihydropyrimidinase deficiency is a rare autosomal recessive disease affecting the second step of pyrimidine degradation. It is caused by mutations in the DPYS gene. Only approximately 30 cases have been...
8.
Mizuguchi M, Ikeda H, Kagitani-Shimono K, Yoshinaga H, Suzuki Y, Aoki M, et al.
Brain Dev
. 2018 Aug;
41(1):1-10.
PMID: 30060984
Background: Epilepsy and autism spectrum disorder (ASD) are the common neurological manifestations of tuberous sclerosis complex (TSC). EXIST-3 study has recently demonstrated that everolimus reduces seizures in patients with TSC...
9.
Yoshinaga H, Oka M, Akiyama T, Endoh F, Akiyama M, Hayashi Y, et al.
No To Hattatsu
. 2018 Jul;
5-9:5-9.
PMID: 30011146
Objective: Tuberous sclerosis complex (TSC) is a multisystem disorder characterized by the formation of hamartoma in multiple organ systems of the body. However, without a well-established cooperative system involving related...
10.
Kobayashi K, Endoh F, Agari T, Akiyama T, Akiyama M, Hayashi Y, et al.
Epilepsia Open
. 2018 Mar;
2(2):260-266.
PMID: 29588955
We investigated the relationship between the scalp distribution of fast (40-150 Hz) oscillations (FOs) and epileptogenic lesions in West syndrome (WS) and related disorders. Subjects were 9 pediatric patients with...